Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway

Michael Lahn, Stephan Herbertz, J. Scott Sawyer, Anja J Stauber, Ivelina Gueorguieva, Kyla E Driscoll, Shawn T Estrem, Ann L Cleverly, Durisala Desaiah, Susan C Guba, Karim A Benhadji, Christopher A Slapak
  • Drug Design Development and Therapy, August 2015, Dove Medical Press
  • DOI: 10.2147/dddt.s86621

The authors haven't finished explaining this publication. If you are the author, sign in to claim or explain your work.

open access logoRead Publication

The following have contributed to this page: Dr Michael Lahn

In partnership with: